多组学驱动的精准策略克服胃肠道恶性肿瘤中 CAR-T 治疗的局限性
Multi-Omics-Enabled Precision Strategies for Overcoming CAR-T Therapy Limitations in Gastrointestinal Malignancies.
FRONTIER PAPERS
Multi-Omics-Enabled Precision Strategies for Overcoming CAR-T Therapy Limitations in Gastrointestinal Malignancies.
Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity.
Modulation of Oncogenic NOTCH Signaling in Highly Aggressive Malignancies by Targeting the γ-Secretase Complex: A Systematic Review.
Claudin-18.2: Molecular mechanisms to clinical translation in solid tumors (Review).
Preclinical application of a CD155 targeting chimeric antigen receptor T cell therapy for digestive system cancers.
Dual targeting chimeric antigen receptor cells enhance antitumour activity by overcoming T cell exhaustion in pancreatic cancer.
Development of tri-cistronic CLDN18.2 CAR-T cells incorporating PD-1/CD28 switch and cyclophilin A for enhanced solid tumor immunotherapy.
Dark horse target Claudin18.2 opens new battlefield for pancreatic cancer.
共 9 条
MEMBER ACCOUNT
登录成功会直接打开下一页。